These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a. Palanisamy N; Danielsson A; Kokkula C; Yin H; Bondeson K; Wesslén L; Duberg AS; Lennerstrand J Antiviral Res; 2013 Jul; 99(1):12-7. PubMed ID: 23648709 [TBL] [Abstract][Full Text] [Related]
9. Clinical relevance of the HCV protease inhibitor-resistant mutant viral load assessed by ultra-deep pyrosequencing in treatment failure. Mohamed S; Bourliere M; Benali S; Oules V; Castellani P; Khiri H; Camus C; Penaranda G; Chiche L; Gonzalez D; Sayada C; Olive D; Halfon P J Clin Virol; 2016 May; 78():36-43. PubMed ID: 26971166 [TBL] [Abstract][Full Text] [Related]
10. Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning. Cuypers L; Libin P; Schrooten Y; Theys K; Di Maio VC; Cento V; Lunar MM; Nevens F; Poljak M; Ceccherini-Silberstein F; Nowé A; Van Laethem K; Vandamme AM Infect Genet Evol; 2017 Sep; 53():15-23. PubMed ID: 28499845 [TBL] [Abstract][Full Text] [Related]
11. A boceprevir failure in a patient infected with HCV genotype 1g: importance and limitations of virus genotyping prior to HCV protease-inhibitor-based therapy. Cento V; Landonio S; De Luca F; Di Maio VC; Micheli V; Mirabelli C; Niero F; Magni C; Rizzardini G; Perno CF; Ceccherini-Silberstein F Antivir Ther; 2013; 18(4):645-8. PubMed ID: 23411358 [TBL] [Abstract][Full Text] [Related]
12. Investigation of NS3 Protease Resistance-Associated Variants and Phenotypes for the Prediction of Treatment Response to HCV Triple Therapy. Dietz J; Rupp D; Susser S; Vermehren J; Peiffer KH; Filmann N; Bon D; Kuntzen T; Mauss S; Grammatikos G; Perner D; Berkowski C; Herrmann E; Zeuzem S; Bartenschlager R; Sarrazin C PLoS One; 2016; 11(6):e0156731. PubMed ID: 27281344 [TBL] [Abstract][Full Text] [Related]
14. Low frequency of drug-resistant virus did not affect the therapeutic efficacy in daclatasvir plus asunaprevir therapy in patients with chronic HCV genotype-1 infection. Kinugasa H; Ikeda F; Takaguchi K; Mori C; Matsubara T; Shiraha H; Takaki A; Iwasaki Y; Toyooka S; Yamamoto K Antivir Ther; 2016; 21(1):37-44. PubMed ID: 26115551 [TBL] [Abstract][Full Text] [Related]
15. Previous failure of interferon-based therapy does not alter the frequency of HCV NS3 protease or NS5B polymerase inhibitor resistance-associated variants: longitudinal analysis in HCV/HIV co-infected patients. Sede MM; Laufer NL; Quarleri J Int J Antimicrob Agents; 2015 Aug; 46(2):219-24. PubMed ID: 26100213 [TBL] [Abstract][Full Text] [Related]
16. Development of a high-throughput pyrosequencing assay for monitoring temporal evolution and resistance associated variant emergence in the Hepatitis C virus protease coding-region. Irving WL; Rupp D; McClure CP; Than LM; Titman A; Ball JK; Steinmann E; Bartenschlager R; Pietschmann T; Brown RJ Antiviral Res; 2014 Oct; 110():52-9. PubMed ID: 25057759 [TBL] [Abstract][Full Text] [Related]
17. Boceprevir: an oral protease inhibitor for the treatment of chronic HCV infection. Trembling PM; Tanwar S; Dusheiko GM Expert Rev Anti Infect Ther; 2012 Mar; 10(3):269-79. PubMed ID: 22397560 [TBL] [Abstract][Full Text] [Related]
18. Primer ID ultra-deep sequencing reveals dynamics of drug resistance-associated variants in breakthrough hepatitis C viruses: relevance to treatment outcome and resistance screening. Barnard R; Chopra A; James I; Blinco J; Watson MW; Jabara CB; Hazuda D; Lemon SM; Mallal S; Gaudieri S Antivir Ther; 2016; 21(7):567-577. PubMed ID: 27219495 [TBL] [Abstract][Full Text] [Related]
19. Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b. Vermehren J; Susser S; Lange CM; Forestier N; Karey U; Hughes E; Ralston R; Tong X; Zeuzem S; Sarrazin C J Viral Hepat; 2012 Feb; 19(2):120-7. PubMed ID: 22239501 [TBL] [Abstract][Full Text] [Related]
20. Evolution of multi-drug resistant HCV clones from pre-existing resistant-associated variants during direct-acting antiviral therapy determined by third-generation sequencing. Takeda H; Ueda Y; Inuzuka T; Yamashita Y; Osaki Y; Nasu A; Umeda M; Takemura R; Seno H; Sekine A; Marusawa H Sci Rep; 2017 Mar; 7():45605. PubMed ID: 28361915 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]